The potential role of PPARγ in thepathogenesis of some human lipodystrophies has been demonstrated in recentstudies finding dominant negative and loss-of-function mutations to affect theligand-binding domain of PPARγ in non-HIV patients with partial lipodystrophy,hepatic steatosis, dyslipidemia, and insulin resistance [13]. This evidence concerns the gene PPARG and fatty liver disease.